Dopamine News and Research

RSS

Dopamine is a hormone and neurotransmitter occurring in a wide variety of animals, including both vertebrates and invertebrates. In the brain, this phenethylamine functions as a neurotransmitter, activating the five types of dopamine receptors — D1, D2, D3, D4 and D5, and their variants. Dopamine is produced in several areas of the brain, including the substantia nigra and the ventral tegmental area. Dopamine is also a neurohormone released by the hypothalamus. Its main function as a hormone is to inhibit the release of prolactin from the anterior lobe of the pituitary. Dopamine has many functions in the brain, including important roles in behavior and cognition, motor activity, motivation and reward, inhibition of prolactin production (involved in lactation), sleep, mood, attention, and learning. Dopaminergic neurons (i.e., neurons whose primary neurotransmitter is dopamine) are present chiefly in the ventral tegmental area (VTA) of the midbrain, substantia nigra pars compacta, and arcuate nucleus of the hypothalamus.

Brain works best when cells keep right rhythms

It is said that each of us marches to the beat of a different drum, but new Stanford University research suggests that brain cells need to follow specific rhythms that must be kept for proper brain functioning.

26 Apr 2009

MicroRNA may link smoking risk gene to neurobiology of addiction

During the past several years, significant progress has been made in identifying susceptibility genes for nicotine dependence through genetic linkage and association analyses.

23 Apr 2009

Discovery of key processes in the brain that control perception of emotional events

Research performed by Nicole Lauzon and Dr. Steven Laviolette of the Schulich School of Medicine & Dentistry at The University of Western Ontario has found key processes in the brain that control the emotional significance of our experiences and how we form memories of them.

20 Apr 2009

Laughter improves health

The connection between the body, mind and spirit has been the subject of conventional scientific inquiry for some 20 years.

20 Apr 2009

Wrist acupuncture prevents postoperative nausea and vomiting

Up to 80 percent of patients who have surgery complain of nausea and vomiting afterwards, but stimulating an acupoint in their wrists can help reduce these symptoms, finds a new evidence review.

14 Apr 2009

Dopamine agonists trigger destructive behaviors

A new study conducted at Mayo Clinic reports that one in six patients receiving therapeutic doses of certain drugs for Parkinson's disease develops new-onset, potentially destructive behaviors, notably compulsive gambling or hypersexuality.

9 Apr 2009

Obesity and overweight linked to greater risk of restless legs syndrome

A new study shows both obesity and a large belly appear to increase the risk of developing restless legs syndrome (RLS), a common sleep disorder characterized by an irresistible urge to move your legs.

6 Apr 2009

Researchers find direct link between bursting activity of midbrain dopamine neurons and behavior

Researchers are one step closer to understanding the neurobiology that allows people to successfully learn motivated behaviors by associating environmental cues with rewarding outcomes, according to a study published yesterday in the Proceedings of the National Academy of Sciences ' online Early Edition.

6 Apr 2009

Schizophrenia could be caused by faulty signalling in the brain

In the biggest study of its kind, scientists looking in detail at brain samples donated by people with the condition have identified 49 genes that work differently in the brains of schizophrenia patients compared to controls.

2 Apr 2009

Blocking hunger hormone helps fight cocaine addiction

UC Irvine pharmacological researchers have discovered that blocking a hormone related to hunger regulation can limit cocaine cravings.

1 Apr 2009

CSHL neuroscientists propose project to comprehensively map mammalian brain circuits

Thirty-seven scientists from Cold Spring Harbor Laboratory (CSHL) and 20 other major research institutions in the U.S. and Europe have issued a major challenge to the neuroscience community.

1 Apr 2009

Eli Lilly announces inconclusive study results for mGlu2/3 in acute schizophrenia

Eli Lilly and Company has announced inconclusive Phase II clinical trial results from Study HBBI investigating LY2140023 monohydrate, also known as mGlu2/3, for the treatment of patients suffering from acute schizophrenia.

29 Mar 2009

Non-invasive brain scanning technique may trace development of Parkinson's disease

While finding a biomarker for Parkinson's disease that would let physicians screen for or track its progression remains an elusive goal, a team led by a University of Illinois at Chicago neuroscientist has shown that a non-invasive brain scanning technique offers promise.

24 Mar 2009

Experimental Parkinson's therapy may have robust weight-loss effect

A growth factor used in clinical experiments to rescue dying brain cells in Parkinson patients may cause unwanted weight loss if delivered to specific areas of the brain, according to University of Florida researchers in the March online edition of Molecular Therapy.

24 Mar 2009

p11 protein may lead to faster acting antidepressants

Research conducted by Nobel laureate Paul Greengard, Medical Director of The Michael Stern Parkinson's Research Center at The Rockefeller University, Dr. Jennifer L. Warner-Schmidt in New York and colleagues in Sweden, demonstrated in the Journal of Neuroscience that the brain protein called p11 could lead pharmaceutical companies to develop anti-depression drugs that begin working within hours or days rather than the weeks or even months required by current drugs.

23 Mar 2009

FDA approves Symbyax for treatment-resistant depression

The U.S. Food and Drug Administration (FDA) has approved a new indication for Symbyax (olanzapine and fluoxetine HCl capsules), Eli Lilly and Company has announced.

23 Mar 2009

Novel stimulation method sparks hope for Parkinson's disease sufferers

A novel stimulation method, the first potential therapy to target the spinal cord instead of the brain, may offer an effective and less invasive approach for Parkinson's disease treatment, according to pre-clinical data published in the journal Science by researchers at Duke University Medical Center.

20 Mar 2009

Naltrexone can reduce relapse rates among alcohol-dependence patients

Naltrexone, an opioid antagonist approved in 1994 by the U.S. Food and Drug Administration for alcohol-dependence (AD) treatment, can reduce relapse rates among AD patients.

20 Mar 2009

Low to moderate drinking releases 'feel-good' endorphins in the brain, not heavy drinking

Scientists know that alcohol affects the brain, but the specifics remain unclear.

20 Mar 2009

Drug being used to improve cognition affects dopamine, suggesting potential for abuse

Preliminary research in healthy men suggests that the narcolepsy drug modafinil, increasingly being used to enhance cognitive abilities, affects the activity of dopamine in the brain in a way that may create the potential for abuse and dependence, according to a study in the March 18 issue of JAMA.

17 Mar 2009